Feed / CRMD

CorMedix Inc.

CRMD

Healthcare · 7.95 -2.1% today

Isolated · not yet confirmedMarket checked 10 Sept, 15:55 GMT-4

Market read

CorMedix Inc.'s current read is isolated; its market group is not confirming.

No new filing conclusion is available. 0 of 4 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.

Company-2.1% todayVolume comparison unavailable
Market group0 of 4 activeFinancial Technology Solutions · unavailable
Disclosed network0 of 3 confirmingNo filing-linked name is confirming now
What would change this read
  • CRMD's market-adjusted activity becomes unusual and at least one connected name confirms.

Invalidation: The isolated read changes if CRMD's group or a disclosed connection begins moving with it.

Watch this read

Research brief

The story so far

Healthcare · Biotechnology

No new filing conclusion is available. 0 of 4 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.

Evidence that supports

No thresholded supportive filing evidence is available yet.

Evidence that challenges

No thresholded adverse filing evidence is available yet.

What would clarify the read
  • CRMD's market-adjusted activity becomes unusual and at least one connected name confirms.

Company research

Understand the business, not just the ticker

As of Sep 11, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods9
Price observations319
Usable filing statements80
Verified relationships3
Evidence supporting the case
  • Latest annual revenue changed +617.0% year over year.
  • Operating margin changed +99.6 percentage points in the latest annual period.
  • Net margin changed +93.6 percentage points in the latest annual period.
  • Operating cash flow covered net income at 1.07x in the latest annual period.
Evidence challenging the case
  • Diluted shares increased 36.4% in the latest annual period.
Questions before a position
  • P/E is 89% below the available filing-peer median; determine whether growth and quality justify the difference.
  • EV/sales is 78% below the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context

Price as of Sep 10, 2026

7.95
6m+11.5%12m-43.8%24m
Annual trajectory

Reported annual revenue and per-share history. This is accounting history, not a forecast.

PeriodRevenueYoYDiluted EPSShare change
2020-12-31$239,231-15.5%
2021-12-31$190,936-20.2%$-0.75
2022-12-31$65,408-65.7%$-0.74+6.9%
2024-12-31$43.5M+66362.8%$-0.30+46.2%
2025-12-31$311.7M+617.0%$2.04+36.4%

What management says matters

Persistent and emerging business drivers

Credit and interest ratesmixed · 3 filings
The change was primarily due to interest expense on our $150.0 million aggregate principal amount of convertible senior notes due 2030, which were issued during the third quarter of 2025, and partially offset by interest income on cash and short-term investme…
10-Q · May 14, 2026
Foreign exchangenegative · 2 filings
Foreign exchange transaction income (loss) for the three and nine months ended September 30, 2025 and 2024 were due to the re-measuring of transactions denominated in a currency other than our functional currency.
10-Q · Nov 12, 2025
Legal and regulatory exposurepositive · 2 filings
In addition, general and administrative expense increased due to higher branded prescription drug fees driven by growth in product sales, as well as higher litigation-related costs.
10-Q · May 14, 2026
Product pipeline and R&Dmixed · 2 filings
Contract Revenue As a result of the Merger, we recognize revenue associated with Melinta’s license and collaboration agreements for the research and development and/or commercialization of its therapeutic products in the form of licensing fees, milestone paym…
10-Q · Nov 12, 2025

Valuation discipline

Descriptive valuation snapshot

Price/sales 2.0× · EV/sales 1.6×. Comparisons use only industry-matched filing peers.

Scenario scaffold

Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.

Price action

How the market is pricing the story

7.95-2.1% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for CRMD. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Filing analysis

No comparable filing assessment is available yet

Jodie has not yet found a suitable current-versus-prior filing comparison for CRMD. This does not mean the latest filing was neutral or immaterial.

Business ecosystem

The relationships behind CRMD

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

TGTTarget CorporationpartnerAug 7, 2025

Under the terms and subject to the conditions set forth in the Merger Agreement, at the effective time of the Merger (the “Effective Time” and the date of the Effective Time, the “Closing Date”), the Company will (i) pay to the Melinta equityholders (includin…

LGNDLigand Pharmaceuticals IncorporatedsupplierNov 12, 2025

Additionally, Melinta has agreed to purchase our requirements of Captisol from Ligand for use in a Baxdela product, with pricing established pursuant to a tiered pricing schedule.

TLPHFiling-linked nameinvesteeNov 12, 2025

Other income represents the change in fair value for its marketable equity securities in Talphera, a publicly-traded biotechnology company, from the date that the stock was acquired to September 30, 2025.

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

CRMD is currently a Follower in the organic co-movement group Financial Technology Solutions. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

This group is retained as the last observed read for CRMD; it is not active in the latest market snapshot.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.